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Background: Recent neuroimaging studies have investigated the brain involvement in patients with Crohn's
disease (CD) and Ulcerative Colitis (UC). Functional studies found abnormalities in cognitive and emotional
functions in CD and UC, while a voxel based morphometry (VBM) study found morphological changes in CD. We
conducted a VBM study to compare the gray matter (GM) volume of UC patients and controls.
Methods: Eighteen UC patients in remission and eighteen healthy controls underwent structural MRI. VBM is a fully
automated technique allowing identification of regional differences in the amount of GM, which enables an
objective analysis of the whole brain. VBM was used for comparisons between patients and controls.
Results: UC patients were all in remission and had a mild clinical course. There were no differences between
patients and controls in GM volume.
Conclusion: The brain morphology of patients with UC in remission is similar to controls. The lack of GM
abnormalities in UC patients might reflect the mild clinical course of the inflammatory bowel disorder. Further
research involving patients with different degrees of disease severity or during flares could shed more light on
potential brain structural changes in UC.
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Ulcerative colitis (UC) and Crohn’s disease (CD) are
chronic, relapsing and remitting disorders of the bowel
collectively labelled as inflammatory bowel diseases (IBD).
The main symptoms of IBD include bloody diarrhoea, ab-
dominal pain, fever, and weight loss. IBD are associated
with stress [1,2], emotional disturbances [3-5], psycho-
logical disorders, and impaired cognitive functioning [6].
The plausible neural substrate for these comorbidities
have been investigated in recent research focused on the
brain involvement in IBD patients [2,5,7]. In patients with
CD, both functional and morphological neuroimaging
studies have been conducted. Indeed, in these patients, a* Correspondence: alessandro.furey@tiscali.it
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unless otherwise stated.recent case-control, functional magnetic resonance im-
aging (fMRI) study has shown impaired neural activity in
the mid temporal lobe, in the insula, putamen, and cere-
bellum in response to stressful stimuli [2]. In addition,
brain morphological abnormalities were found in CD
patients in a voxel based morphometry (VBM) study
[7]. VBM is a fully automated technique enabling an ob-
jective study of the whole brain that allows identifica-
tion of differences in the amount of grey matter (GM)
[8]. Although the underlining mechanisms for the brain
GM changes in CD need to be thoroughly elucidated,
pain and inflammatory mediators have been implicated
[7]. We hypothesized that these factors might promote
GM changes in UC patients.
In patients with UC, despite an fMRI study that has
shown dysfunction in the emotional processing charac-
terized by abnormalities in the activity of the amygdala,l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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studies still have not been conducted.
We performed an explorative MRI study using VBM
to compare the GM volume of eighteen UC patients in
remission and eighteen healthy controls.
Methods
Participant recruitment
This study was approved by the local Ethics Committee
and all participants signed an informed consent statement.
Physicians attending the IBD Unit of the Policlinico-
Hospital in Modena examined and enrolled all partici-
pants. Eligible UC patients were consecutively recruited
when they met the inclusion and exclusion criteria. Clin-
ical and endoscopic data were obtained for all enrolled pa-
tients from routinely conducted visits and colonoscopies.
All participants were screened for neurological and psy-
chiatric disorders using a semi-structured interview based
on the diagnostic and statistical manual of mental disor-
ders (DSM IV).
Inclusion criteria
Age > 18, < 65; UC diagnosed at least one year prior to
enrollment; clinical remission for at least 6 months;
right-handed.
Patients with active disease or recent flares were excluded
because medications used during flares, such as steroids [9]
and opioids [10], may induce acute GM changes.Exclusion criteria
Signs of disease activity (based on clinical and endo-
scopic data); use of corticosteroids, biologics, and psy-
chotropic medications in the previous 6 months; current
or prior history of neurological, psychiatric disease;
chronic pain syndromes; claustrophobia; presence of me-
tallic implants in the body.
At recruitment we collected: age, gender, education,
disease location, extra-intestinal manifestations, smoking
history, history of intestinal surgery (including append-
ectomy), clinical colitis activity index (CAI) [11], endo-
scopic parameters of disease activity, treatment with
biologics, maintenance treatments, IBS symptoms.
Patients were asked to rate the severity of pain symp-
toms at recruitment and during flares. Two visual
analogue scales (VAS) were used in which 0 corresponded
to "no pain", 3 to "mild pain", 6 to "moderate pain", and 10
to "worst possible pain".Control group A group of 18 healthy subjects (10 fe-
male) were recruited with advertisements from among the
staff of Bologna and Modena universities. They underwent
the same screening procedures as the UC patients.Neuroimaging protocol
Scanning was performed at the Department of Biomedical,
Metabolic and Neurological sciences of Modena University,
Baggiovara Hospital. T1- weighted images were acquired
using a 3 Tesla Philips Intera system. A SPGR pulse se-
quence [echo time (TE) = 4.6, repetition time (TR) =
9.9 ms] was used. One hundred seventy contiguous slices
were acquired (voxel size = 1 × 1 × 1 mm). VBM was used
to identify GM changes between groups. The Matlab 7.1
and SPM8 (Wellcome Trust Centre for Neuroimaging,
London, UK) software were used for data analysis.
VBM procedure Preprocessing: The pre-processing pro-
cedure was conducted according to the vbm8 toolbox
(http://dbm.neuro.uni-jena.de/vbm/vbm8-for-spm8/) as
implemented in SPM8. The optimized method for vbm8
comprised several consecutive steps: Normalization, seg-
mentation, modulation, and smoothing. The normalization
process transforms all the images to the same stereotactic
space. This is achieved by registering each of the images to
the same template image, the Montreal Neurological Insti-
tute/International Consortium for Brain Mapping (MNI/
ICBM) 152 standard using linear transformations. The
images were segmented in GM, white matter (WM), and
cerebrospinal fluid (CSF) volumes. With respect to this
pre-processing step, vbm8 differs from the standard VBM
procedure. Indeed, segmentation is performed without tis-
sue priors, thus increasing classification accuracy. Volumes
were then modulated with Jacobian determinants. Modula-
tion involves scaling by the amount of contraction, so that
the total amount of GM in the modulated GM volume re-
mains the same, as it would be in the original images. Fi-
nally, the GM images were smoothed by convolving with
an isotropic Gaussian kernel (12 × 12 × 12 mm).
Whole brain analysis: The total GM volumes of
normalized-modulated-smoothed images were compared
between groups using a two sample T-test. To remove
the confounding effects of different brain sizes, we used
modulated images that corrected for non-linear warping
only. In addition, we modelled the total amount of GM,
WM, and CSF as nuisance parameters (additive effects).
Modulation is recommended if interested in volume
changes rather than differences in concentration (or
density). The statistical threshold was set at p < 0.05
family wise error (FWE) corrected.
Power analysis: A power analysis was conducted using
the software frmipower testing at an alpha-threshold of
p < 0.05 [12].Statistical analysis for non-imaging variables
Statistics were carried out using SPSS software (Chicago,
IL). T-test was used for comparisons between the two
groups and χ2 (chi-square) for categorical variables.
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Participants
None of the participants were smokers at recruitment.
No socio-demographic differences were observed be-
tween patients (N = 18) and controls (N = 18) (Table 1).
Patient characteristics
Endoscopic and clinical data were available for all patients.
Patients were all in clinical remission and rated the pain
"mild" (1.66 ± 0.48, range 1-2) at recruitment. From the
diagnosis, 15 patients had 1 flare and 3 had no flares. Dur-
ing flares pain was rated “severe” (7.94 ± 0.80, range 7-10).
All patients were in maintenance treatment with 5-amino-
salicylic-acid agents. No patients had IBS symptoms. The
clinical characteristics of the patients are shown in Table 1.
VBM
There were no differences in the GM volume of the pa-
tients and controls when using the total intracranial vol-
ume (TIV) and age as covariates of non-interest.
A power analysis was therefore performed using the pre-
viously detected regions of significantly decreased GM vol-
ume of CD patients and controls (7) as regions of interest
(ROIs). The calculation revealed that the probability of de-
tecting a significant effect in each ROI was the following:
Right and left superior and medial frontal gyrus (MNI coor-
dinates: 4 45 35), left middle and superior frontal gyrus
(MNI coordinates: -22 25 5), right middle and superiorTable 1 Socio-demographic and clinical characteristics of







Age (years) 39.06 (±9.64) 36.89 (±11.01) 0.54
Sex (male/female) 10/8 10/8 1
Education (years) 12.56 (±2.17) 14.28 (±4.39) 0.15
Clinical characteristics
Duration of illness (years) 10.33 (6.59)
Duration of remission (years) 3.94 (4.65)








Previous surgery Previously treated 0
Never treated 18
Use of biologics Previously treated 0
Never treated 18
Values denote mean (±Standard Deviation) or numbers of subjects.frontal gyrus (MNI coordinates: 27 53 12) power: 0.65; right
anterior cingulate (MNI coordinates: 4 28 20) power: 0.58.
Discussion
In this study, the GM volume of UC patients in remis-
sion and healthy controls was compared using VBM.
The brain involvement of IBD patients has been investi-
gated in both functional and structural neuroimaging
studies [2,5,7]. FMRI studies conducted for patients with
UC and CD found abnormalities in emotional and cog-
nitive functions [2,5], while brain morphological changes
were found in CD patients in a recent VBM study [7].
In the present study, compared to controls, brain mor-
phological changes did not emerge in UC patients. In pa-
tients with CD, the brain volumetric changes were
characterized by GM volume reductions in the midcingu-
late cortex and in a portion of the frontal lobe. In addition,
the GM volumes of the cortical and subcortical areas were
negatively correlated with disease duration, which suggests
progressive volumetric changes in brain areas involved in
the nociception, emotional, and cognitive functions of pa-
tients [7]. Overall, in VBM studies, a decrease in GM
could be due to neural or glial cell apoptosis, decreased
cell size, decreased dendritic density, or changes in inter-
stitial fluid. In CD, the chronicity of the disorder, pain, and
inflammatory mediators have been implicated in the GM
volumetric changes [7,13]. Indeed, the chronic abdominal
pain associated to the inflammatory activity determines
abundant inputs towards the pain matrix, the distributed
network of brain structures involved in nociception. This
overstimulation, in turn, might induce neural loss, a
phenomenon known as excito-toxicity [13].
Furthermore, in IBD, the overproduction of inflammatory
cytokines is believed to promote GM changes by inducing
apoptosis in astrocytes and oligodendrocytes, decreased
neurogenesis and increased glutamatergic activation, and
oxidative stress [14,15]. Although circulating cytokines can-
not cross the blood brain barrier, they can propagate in-
flammatory signals within the brain through the activation
of the endothelial and glial cells or perivascular macro-
phages [16]. Finally, intestinal inflammatory signals may
reach the brain via the brain gut axis, the anatomo-
functional substrate for bidirectional communications
between the brain and the gastrointestinal tract [17,18]. In-
deed, the afferent fibers of the vagus nerve are also a target
of cytokines [19,20].
The patients with UC enrolled for this study were all in
remission and overall had a mild clinical course. Indeed,
they had no more than one inflammatory exacerbation
from the diagnosis, and none underwent surgery, had ex-
traintestinal manifestations, or were treated with biologics.
In addition, pain was mild at recruitment and pain symp-
toms were judged severe by all patients only during flares.
Therefore, the lack of GM abnormalities in UC patients
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bowel disorder rather than differences in the brain involve-
ment between UC and CD. The enrollment of patients
without severe UC or not complaining of persistent pain
symptoms limited the investigation of the possible impact
of these clinical parameters in the development of potential
brain structural changes in UC. Furthermore, the results of
the power analysis suggest that the number of enrolled UC
patients represents another limitation of the present study.
Conclusion
In conclusion, the GM changes previously found in a
group of CD patients [7] were not replicated in the
present explorative VBM study, conducted with patients
with UC in remission and of mild clinical course. These
findings suggest a key role for the severity of the bowel
disorder in the development of the morphological neural
changes of IBD patients.
Further research involving an increased number of UC
patients is needed to shed more light on the brain involve-
ment in UC. Moreover, the enrollment of patients with a
severe disease course or active disease could pave the way
to further studies aimed at investigating the plausible
neural substrate for the development of emotional distur-
bances or impaired cognitive functions in IBD.
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